2019
DOI: 10.1016/s1569-9056(19)31186-8
|View full text |Cite
|
Sign up to set email alerts
|

Long non-coding RNA SOX2OT promotes stemness characteristics and drug-resistance of bladder cancer cells by modulating SOX2

et al.
Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2022
2022
2022
2022

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(2 citation statements)
references
References 0 publications
0
2
0
Order By: Relevance
“…There is some supporting evidence highlighting SOX2OT association with drug resistance to other chemotherapy agents with a different mechanism. It has been reported that SOX2OT inhibition can restrict the bladder cancer stem cell (CD44+, ALDH1+) self-renewal and cisplatin resistance by SOX2 regulation [28]. Wang et al showed that EGCG (polyphenol derived from green tea), which targets SOX2OT, can synergize doxorubicin toxicity in osteosarcoma cells by autophagy and stemness inhibition [27].…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…There is some supporting evidence highlighting SOX2OT association with drug resistance to other chemotherapy agents with a different mechanism. It has been reported that SOX2OT inhibition can restrict the bladder cancer stem cell (CD44+, ALDH1+) self-renewal and cisplatin resistance by SOX2 regulation [28]. Wang et al showed that EGCG (polyphenol derived from green tea), which targets SOX2OT, can synergize doxorubicin toxicity in osteosarcoma cells by autophagy and stemness inhibition [27].…”
Section: Discussionmentioning
confidence: 99%
“…One of the master modulators of pluripotency in cancer stem cells, SOX2 is located in an intronic region of SOX2OT long non-coding RNA. SOX2OT is mapped on a highly conserved region in chromosome 3q26.3 in humans [21,22] and has various cellular functions in embryogenesis and neuronal development [23], cancer cell proliferation [24,25], metastasis [26], and drug resistance [27,28]. Previous studies support overexpression of SOX2OT in tumor tissues of the breast [29], esophageal [30], lung [24,31], and hepatocellular [26].…”
Section: Introductionmentioning
confidence: 99%